Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion
Abstract Background Most patients with advanced prostate cancer develop bone metastases, which often result in painful and debilitating skeletal-related events. Inhibitors of bone resorption, such as bisphosphonates and denosumab, can each reduce the incidence of skeletal-related events and delay th...
Main Authors: | Jean-Jacques Body, Roger von Moos, Daniela Niepel, Bertrand Tombal |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-09-01
|
Series: | BMC Urology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12894-018-0393-9 |
Similar Items
-
Refractory Shock Secondary to Denosumab-induced Severe Hypocalcaemia
by: Nouran Eshak, et al.
Published: (2022-12-01) -
Improving Bone Health in Patients with Metastatic Prostate Cancer with the Use of Algorithm-Based Clinical Practice Tool
by: Kamal Kant Sahu, et al.
Published: (2022-11-01) -
Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
by: Jiaqi Wu, et al.
Published: (2018-08-01) -
Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
by: Chuanjian Yuan, et al.
Published: (2023-06-01) -
Potential protective effect of zoledronic acid when switching from long-term therapy of osteoporosis with denosumab
by: O. V. Yakushevskaya
Published: (2021-01-01)